Clinical trials are currently conducted to test the efficacy of the anti-CD47 monoclonal antibody magrolimab in combination with other anti-myeloma drugs in relapsed and therapy refractory MM patients (168). This evidence concerns the gene CD47 and plasma cell myeloma.